Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus AMINOSYN II 3 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus AMINOSYN II 3 5.
AMINOSYN II 10% IN PLASTIC CONTAINER vs AMINOSYN II 3.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 10% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintenance of nitrogen balance, and tissue repair in parenteral nutrition.
Amino acids serve as substrates for protein synthesis, providing essential and non-essential nitrogen sources for anabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 7-12 g amino acids per kg body weight per day (0.7-1.2 g/kg/day) for adults with normal renal function; typically administered as a 10% solution at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion of 250-500 mL/day (8.75-17.5 g amino acids) as a component of parenteral nutrition; rate up to 125 mL/hour; titrate based on metabolic response.
None Documented
None Documented
Variable depending on individual amino acids; typical of infused amino acids: 0.5-2 hours for most, with clinical context of continuous infusion achieving steady-state within 24 hours.
Terminal elimination half-life of individual amino acids ranges from 10 to 30 minutes for most, with glutamine and arginine slightly longer (30–45 min). No defined half-life for the mixture; clinically, steady-state achieved in 2–3 hours with continuous infusion.
Amino acids are metabolized; excess nitrogen is excreted renally as urea (70-90%) and to a lesser extent in feces (5-10%).
Renal: 95% of infused amino acids are reabsorbed; excess amino acids are deaminated and urea is excreted renally. Fecal/Biliary: negligible (<1%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution